Migraine represents the third most prevalent and the seventh most disabling human disorder. Approximately 30% of migraine patients experience transient, fully reversible, focal neurological symptoms (aura) preceding the attack.
Recent Advances:
Awareness of the hypothesis that migraine actually embodies a spectrum of illnesses—ranging from episodic to chronic forms—is progressively increasing and poses novel challenges for clarifying the underlying pathophysiological mechanisms of migraine as well as for the development of novel therapeutic interventions. Several theories have evolved to the current concept that a combination of genetic, epigenetic, and environmental factors may play a role in migraine pathogenesis, although their relative importance is still being debated.
Critical Issues:
One critical issue that deserves a particular attention is the role of oxidative stress in migraine. Indeed, potentially harmful oxidative events occur during the migraine attack and long-lasting or frequent migraine episodes may increase brain exposure to oxidative events that can lead to chronic transformation. Moreover, a wide variety of dietary, environmental, physiological, behavioral, and pharmacological migraine triggers may act through oxidative stress, with clear implications for migraine treatment and prophylaxis. Interestingly, almost all current prophylactic migraine agents exert antioxidant effects.
Future Directions:
Increasing awareness of the role of oxidative stress and/or decreased antioxidant defenses in migraine pathogenesis and progression to a chronic condition lays the foundations for the design of novel prophylactic approaches, which, by reducing brain oxidative phenomena, could favorably modify the clinical course of migraine. Antioxid. Redox Signal. 28, 1144–1183.
Adam-ViziV. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal, 7: 1140–1149, 2005.
2.
AdanA, ArcherSN, HidalgoMP, Di MiliaL, NataleV, and RandlerC. Circadian typology: a comprehensive review. Chronobiol Int, 29: 1153–1175, 2012.
3.
AkermanS and GoadsbyPJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med, 7: 308ra157, 2015.
4.
AkermanS, WilliamsonDJ, KaubeH, and GoadsbyPJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol, 137: 62–68, 2002.
5.
AlpR, SelekS, AlpSI, TaşkinA, and KoçyiğitA. Oxidative and antioxidative balance in patients of migraine. Eur Rev Med Pharmacol Sci, 14: 877–882, 2010.
6.
AlvaroG and Di FabioR. Neurokinin 1 receptor antagonists—current prospects. Curr Opin Drug Discov Devel, 10: 613–621, 2007.
7.
AnttilaV, WinsvoldBS, GormleyP, KurthT, BettellaF, McMahonG, KallelaM, MalikR, de VriesB, TerwindtG, MedlandSE, TodtU, McArdleWL, QuayeL, KoiranenM, IkramMA, LehtimäkiT, StamAH, LigthartL, WedenojaJ, DunhamI, NealeBM, PaltaP, HamalainenE, SchürksM, RoseLM, BuringJE, RidkerPM, SteinbergS, StefanssonH, JakobssonF, LawlorDA, EvansDM, RingSM, FärkkiläM, ArttoV, KaunistoMA, FreilingerT, SchoenenJ, FrantsRR, PelzerN, WellerCM, ZielmanR, HeathAC, MaddenPA, MontgomeryGW, MartinNG, BorckG, GöbelH, HeinzeA, Heinze-KuhnK, WilliamsFM, HartikainenAL, PoutaA, van den EndeJ, UitterlindenAG, HofmanA, AminN, HottengaJJ, VinkJM, HeikkiläK, AlexanderM, Muller-MyhsokB, SchreiberS, MeitingerT, WichmannHE, AromaaA, ErikssonJG, TraynorBJ, TrabzuniD, RossinE, LageK, JacobsSB, GibbsJR, BirneyE, KaprioJ, PenninxBW, BoomsmaDI, van DuijnC, RaitakariO, JarvelinMR, ZwartJA, CherkasL, StrachanDP, KubischC, FerrariMD, van den MaagdenbergAM, DichgansM, WessmanM, SmithGD, StefanssonK, DalyMJ, NyholtDR, ChasmanDI, and PalotieA; North American Brain Expression Consortium; UK Brain Expression Consortium; International Headache Genetics Consortium. Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nat Genet, 45: 912–917, 2013.
8.
AuroraSK and BrinMF. Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache, 57: 109–125, 2016.
9.
AydinlarEI, DiknePY, TiftikciA, SarueM, AksuM, GunsoyHG, and TozunN. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache, 53: 514–525, 2013.
10.
AytaçB, Coşkun Ö, AlioğluB, DurakZE, BüberS, TapçiE, OcalR, InanLE, Durak İ, and YoldaşTK. Decreased antioxidant status in migraine patients with brain white matter hyperintensities. Neurol Sci, 35: 1925–1929, 2014.
11.
BarbantiP, AuriliaC, Dall'ArmiV, EgeoG, FofiL, and BonassiS. The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients. Cephalalgia, 36: 1334–1340, 2016.
12.
BarbantiP, AuriliaC, EgeoG, and FofiL. Migraine prophylaxis: what is new and what we need?. Neurol Sci, 32: S111–S115, 2011.
BarbantiP, FabbriniG, PesareM, VanacoreN, and CerboR. Unilateral cranial autonomic symptoms in migraine. Cephalalgia, 22: 256–259, 2002.
15.
BarbantiP, FabbriniG, VanacoreN, PesareM, and BuzziMG. Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study. Headache, 43: 400–403, 2003.
16.
BarbantiP, FofiL, AuriliaC, EgeoG, and CaprioM. Ketogenic diet in migraine: rationale, findings and perspectives. Neurol Sci, 38: 111–115, 2017.
17.
BarbantiP, FofiL, Dall'ArmiV, AuriliaC, EgeoG, VanacoreN, and BonassiS. Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial. J Headache Pain, 13: 407–414, 2012.
18.
BarbantiP and EgeoG. Pharmacological trials in migraine: it's time to reappraise where the headache is and what the pain is like. Headache, 55: 439–441, 2015.
19.
BaronEP and TepperSJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache, 50: 1353–1361, 2010.
20.
BarrowcliffeTW, GutteridgeJMC, and DormannTL. The effects of fatty acid autoxidation products on blood coagulation. Thromb Diath Haemorrh, 23: 271–277, 1975.
21.
BartschT, LevyMJ, KnightYE, and GoadsbyPJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain, 109: 367–378, 2004.
22.
BeattieDT, BeresfordIJ, ConnorHE, MarshallFH, HawcockAB, HaganRM, BowersJ, BirchPJ, and WardP. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol, 116: 3149–3157, 1995.
23.
BellIM. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine. J Med Chem, 57: 7838–7858, 2014.
24.
BellamyJL, CadyRK, and DurhamPL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache, 46: 24–33, 2006.
25.
BenemeiS, De CesarisF, FusiC, RossiE, LupiC, and GeppettiP. TRPA1 and other TRP channels in migraine. J Headache Pain, 14: 71, 2013.
26.
BensaidM, FaucheuxBA, HirschE, AgidY, SoubriéP, and Oury-DonatF. Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci Lett, 303: 25–28, 2001.
27.
BhattDK, GuptaS, Jansen-OlesenI, AndrewsJS, and OlesenJ. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia, 33: 87–100, 2013.
28.
BigalM, LiptonR, HollandP, and GoadsbyP. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology, 68: 1851–1861, 2007.
29.
BigalME, DodickDW, RapoportAM, SilbersteinSD, MaY, YangR, LoupePS, BursteinR, NewmanLC, and LiptonRB. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol, 14: 1081–1090, 2015.
30.
BigalME, EdvinssonL, RapoportAM, LiptonRB, SpieringsEL, DienerHC, BursteinR, LoupePS, MaY, YangR, and SilbersteinSD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol, 14: 1091–1100, 2015.
31.
BigalME, LibermanJN, and LiptonRB. Obesity and migraine: a population study. Neurology, 66: 545–550, 2006.
32.
BigalME, TsangA, LoderE, SerranoD, ReedML, and LiptonRB. Body mass index and episodic headaches: a population-based study. Arch Intern Med, 167: 1964–1970, 2007.
33.
BoettgerMK, WeberK, GrossmannD, GajdaM, BauerR, BärKJ, SchulzS, VossA, and GeisC. Spinal tumor necrosis factor alpha neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis: a role for spinal tumor necrosis factor alpha during induction and maintenance of peripheral inflammation. Arthritis Rheum, 62: 1308–1318, 2010.
34.
BorkumJM. Migraine triggers and oxidative stress: a narrative review and synthesis. Headache, 56: 12–35, 2016.
35.
BorroniB, RaoR, LiberiniP, VenturelliE, CossandiM, ArchettiS, CaimiL, and PadovaniA. Endothelial nitric oxide synthase (Glu298Asp) polymorphism is an independent risk factor for migraine with aura. Headache, 46: 1575–1579, 2006.
36.
BoughKJ, WetheringtonJ, HasselB, PareJF, GawrylukJW, GreeneJG, ShawR, SmithY, GeigerJD, and DingledineRJ. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol, 60: 223–235, 2006.
37.
BoulangerLM. Immune proteins in brain development and synaptic plasticity. Neuron, 64: 93–109, 2009.
38.
BoulosC, JiangH, and BalazyM. Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues. J Pharmacol Exp Ther, 293: 222–229, 2000.
39.
BoutagyNE, McMillanRP, FrisardMI, and HulverMW. Metabolic endotoxemia with obesity: it is real and is it relevant?. Biochimie, 124: 11–20, 2016.
40.
BrainSD and GrantAD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev, 84: 903–934, 2004.
41.
BrancoAF, FerreiraA, SimoesRF, Magalhaes-NovaisS, ZehowskiC, CopeE, SilvaAM, PereiraD, SardaoVA, and Cunha-OliveiraT. Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Invest, 46: 285–298, 2016.
BreslauN, DavisGC, and AndreskiP. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res, 37: 11–23, 1991.
44.
BuettnerC, NirRR, BertischSM, BernsteinC, SchainA, MittlemanMA, and BursteinR. Simvastatin and vitamin D for migraine prevention: a randomized, controlled trial. Ann Neurol, 78: 970–981, 2015.
45.
BunnerAE, AgarwalU, GonzalesJF, ValenteF, and BarnardND. Nutrition intervention for migraine: a randomized crossover trial. J Headache Pain, 15: 69, 2014.
46.
BurchardtP, ZurawskiJ, ZuchowskiB, KubackiT, MurawaD, WiktorowiczK, and WysockiH. Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation. Arch Med Sci, 9: 151–158, 2013.
47.
BursteinR, CollinsB, and JakubowskiM. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol, 55: 19–26, 2004.
48.
BursteinR, JakubowskiM, and RauchS. The science of migraine. J Vestib Res, 21: 305–314, 2011.
49.
BurtonGW and TraberMG. Vitamin E: antioxidant activity, biokinetics, and bioavailability. Annu Rev Nutr, 10: 357–382, 1990.
50.
ButterickTA, NixonJP, BillingtonCJ, and KotzCM. Orexin A decreases lipid peroxidation and apoptosis in a novel hypothalamic cell model. Neurosci Lett, 524: 30–34, 2012.
51.
ButtinelliC, LazzaroMP, LenziGL, PaolucciS, and PrencipeM. Correlation between migraine and circulating platelet aggregates. Cephalalgia, 5: 87–88, 1985.
52.
Cárdenas-RodríguezN, Coballase-UrrutiaE, Rivera-EspinosaL, Romero-ToledoA, SampieriA, 3rd, Ortega-CuellarD, Montesinos-CorreaH, Floriano-SánchezE, and Carmona-AparicioL. Modulation of antioxidant enzymatic activities by certain antiepileptic drugs (valproic acid, oxcarbazepine, and topiramate): evidence in humans and experimental models. Oxid Med Cell Longev, 2013:598493, 2013.
53.
CaroleiA, MariniC, and De MatteisG. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet, 347: 1503–1506, 1996.
54.
CasasR, SacanellaE, and EstruchR. The immune protective effect of the mediterranean diet against low grade inflammatory disease. Endocr Metab Immune Disord Drug Targets, 14: 245–254, 2014.
55.
Cernuda-MorollónE, Martínez-CamblorP, RamónC, LarrosaD, Serrano-PertierraE, and PascualJ. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine. Headache, 54: 987–995, 2014.
56.
ChabiA, ZhangY, JacksonS, CadyR, LinesC, HerringWJ, ConnorKM, and MichelsonD. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia, 35: 379–388, 2015.
57.
ChaiNC, GelayeB, TietjenGE, DashPD, GowerBA, WhiteLW, SherAI, and PeterlinBL. Ictal adipokines are associated with pain severity and treatment response in episodic migraine. Neurology, 84: 1409–1418, 2015.
58.
ChaiNC, PeterlinBL, and CalhounAH. Migraine and estrogen. Curr Opin Neurol, 27: 315–324, 2014.
59.
ChaiNC, ScherAI, MoghekarA, BondDS, and PeterlinBL. Obesity and headache: part I—a systematic review of the epidemiology of obesity and headache. Headache, 54: 219–234, 2014.
60.
CharniotJC, Khani-BittarR, AlbertiniJP, GiralP, CherfilsC, CossonC, GuillermE, LeprinceP, GandjbakhchI, and Bonnefont-RousselotD. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments. Int J Cardiol, 168: 132–138, 2013.
61.
ChauvelV, MultonS, and SchoenenJ. Estrogen-dependent effects of 5-hydroxytryptophan on cortical spreading depression in rat: Modelling the serotonin-ovarian hormone interaction in migraine aura. Cephalalgia, 2017. DOI: 10.1177/0333102417690891.
62.
ChoudhuriR, CuiL, YongC, BowyerS, KleinRM, WelchKM, and BermanNE. Cortical spreading depression and gene regulation: relevance to migraine. Ann Neurol, 51: 499–506, 2002.
63.
ChristiansenI, DaugaardD, Lykke ThomsenL, and OlesenJ. Glyceryl trinitrate induced headache in migraineurs—relation to attack frequency. Eur J Neurol, 7: 405–411, 2000.
64.
ChristiansenI, ThomsenLL, DaugaardD, UlrichV, and OlesenJ. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia, 19: 660–667, 1999.
65.
CiancarelliI, Tozzi-CiancarelliMG, Di MassimoC, MariniC, and CaroleiA. Flunarizine effects on oxidative stress in migraine patients. Cephalalgia, 24: 528–532, 2004.
66.
CotrimMD, RibeiroCA, and de Macedo TdosR. Changes in platelet membrane fluidity of migraine patients. Cephalalgia, 13: 99–101, 1993.
67.
CovelliD, PasseriME, LeograndeD, JirilloE, and AmatiL. Sress-related disorders. Curr Med Chem, 12: 1801–1809, 2005.
68.
CowanJ, SintonCM, VarleyAW, WiansFH, HaleyRW, and MunfordRS. Gene therapy to prevent organophosphate intoxication. Toxicol Appl Pharmacol, 173: 1–6, 2001.
69.
CrassardI, ConardJ, and BousserMG. Migraine and haemostasis. Cephalalgia, 21: 630–636, 2001.
70.
CrawfordA, FassettRG, GeraghtyDP, KundeDA, BallMJ, RobertsonIK, and CoombesJS. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene, 501: 89–103, 2012.
71.
CuiXP, YeJX, LinH, MuJS, and LinM. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. Pain Pract, 15: 124–131, 2015.
72.
CuryY, PicoloG, GutierrezVP, and FerreiraSH. Pain and analgesia: the dual effect of nitric oxide in the nociceptive system. Nitric Oxide, 25: 243–254, 2011.
73.
D’ AndreaG, D’ AmicoD, BussoneG, BolnerA, AguggiaM, SaraccoMG, GalloniE, DerivaV, ColavitoD, RosteghinV, and PerinF. The role of tyrosine metabolism in the pathogenesis of chronic migraine. Cephalalgia, 33: 932–937, 2013.
74.
DahgamS, NybergF, ModigL, NaluaiAT, and OlinAC. Single nucleotide polymorphisms in the NOS2 and NOS3 genes are associated with exhaled nitric oxide. J Med Genet, 49: 200–205, 2012.
75.
DahmenN, KastenM, WieczorekS, GencikM, EpplenJT, and UllrichB. Increased frequency of migraine in narcoleptic patients: a confirmatory study. Cephalalgia, 23: 14–19, 2003.
76.
DalesRE, CakmakS, and VidalCB. Air pollution and hospitalization for headache in Chile. Am J Epidemiol, 170: 1057–1066, 2009.
77.
D'AlmeidaV, LoboLL, HipólideDC, de OliveiraAC, NobregaJN, and TufikS. Sleep deprivation induces brain region-specific decreases in glutathione levels. Neuroreport, 9: 2853–2856, 1998.
78.
DamasioH. Migraine, thrombocytopenia, and serotonin metabolism. Lancet, 2: 512–513, 1977.
79.
DaneseE, MontagnanaM, and LippiG. Platelets and migraine. Thromb Res, 134: 17–22, 2014.
80.
DavìG and PatronoC. Platelet activation and atherothrombosis. N Engl J Med, 357: 2482–2494, 2007.
81.
DavignonJ. Apolipoprotein and and atherosclerosis: beyond lipid effect. Arterioscler Thromb Vasc Biol, 25: 267–269, 2005.
82.
DayalS, GuSX, HutchinsRD, WilsonKM, WangY, FuX, and LentzSR. Deficiency of superoxide dismutase impairs protein C activation and enhances susceptibility to experimental thrombosis. Arterioscler Thromb Vasc Biol, 35: 1798–1804, 2015.
83.
de Almeida Rabello OliveiraM, da Rocha AtaídeT, de OliveiraSL, de Melo LucenaAL, de LiraCE, SoaresAA, de AlmeidaCB, and Ximenes-da-SilvaA. Effects of short-term and long-term treatment with medium- and long-chain triglycerides ketogenic diet on cortical spreading depression in young rats. Neurosci Lett, 434: 66–70, 2008.
84.
de MosM, HuygenFJPM, DielemanJP, KoopmanJSHA, StrickerBHC, and SturkenboomMCJM. Medical history and the onset of complex regional pain syndrome (CRPS). Pain, 139: 458–466, 2008.
85.
de O S MansurT, GonçalvesFM, Martins-OliveiraA, SpecialiJG, DachF, LacchiniR, and Tanus-SantosJE. Inducible nitric oxide synthase haplotype associated with migraine and aura. Mol Cell Biochem, 364: 303–308, 2012.
86.
Di LorenzoC, CoppolaG, BracagliaM, Di LenolaD, EvangelistaM, SirianniG, RossiP, Di LorenzoG, SerraoM, ParisiV, and PierelliF. Cortical functional correlates of responsiveness to short-lasting preventive intervention with ketogenic diet in migraine: a multimodal evoked potentials study. J Headache Pain, 17: 58, 2016.
87.
Di LorenzoC, CoppolaG, SirianniG, Di LorenzoG, BracagliaM, Di LenolaD, SiracusanoA, RossiP, and PierelliF. Migraine improvement during short lasting ketogenesis: a proof-of-concept study. Eur J Neurol, 22: 170–177, 2015.
88.
Di LorenzoC, CurràA, SirianniG, CoppolaG, BracagliaM, CardilloA, De NardisL, and PierelliF. Diet transiently improves migraine in two twin sisters: possible role of ketogenesis?. Funct Neurol, 28: 305–308, 2013.
89.
DienerHC, BarbantiP, DahlöfC, ReuterU, HabeckJ, and PodhornaJ. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia, 31: 573–584, 2011.
90.
DodickDW, GoadsbyPJ, SilbersteinSD, LiptonRB, OlesenJ, AshinaM, WilksK, KudrowD, KrollR, KohrmanB, BargarR, HirmanJ, and SmithJ; ALD403 Study Investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol, 13: 1100–1107, 2014.
91.
DodickDW, GoadsbyPJ, SpieringsEL, SchererJC, SweeneySP, and GrayzelDS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol, 13: 885–892, 2014.
92.
DonahueRP, PrineasRJ, DonahueRD, ZimmelP, BeanJA, De CourtenM, CollierG, GoldbergRB, SkylerJS, and SchneidermanN. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami community health study. Diabetes Care, 22: 1092–1096, 1999.
93.
DringenR and HirrlingerJ. Glutathione pathways in the brain. Biol Chem, 384: 505–516, 2003.
94.
DuelandAN. Headache and alcohol. Headache, 55: 1045–1049, 2015.
95.
EdvinssonL and GoadsbyPJ. Neuropeptides in migraine and cluster headache. Cephalalgia, 14: 320–327, 1994.
96.
EdvinssonL. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol, 80: 193–199, 2015.
97.
EdvinssonL. The journey to establish CGRP as a migraine target: a retrospective view. Headache, 55: 1249–1255, 2015.
98.
EdvinssonL. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache, 57: 47–55, 2017.
99.
EisingE, DatsonNA, and van denMaagdenbergAM. Epigenetic mechanisms in migraine: a promising avenue?. BMC Med, 11: 26, 2013.
100.
ErenY, DirikE, NeşelioğluS, andErelÖ. Oxidative stress and decreased thiol level in patients with migraine: cross-sectional study. Acta Neurol Belg, 115: 643–649, 2015.
101.
EstebanJ, RosenDR, BowlingAC, SappP, McKenna-YasekD, O'ReganJP, BealMF, HorvitzHR, and BrownRHJr. Identification of two novel mutations and a new polymorphism in the gene for Cu/Zn superoxide dismutase in patients with amyotrophic lateral sclerosis. Hum Mol Genet, 3: 997–998, 1994.
102.
FanPC, KuoPH, ChangSH, LeeWT, WuRM, and ChiouLC. Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia, 29: 883–890, 2009.
103.
FarelloG, FerraraP, AntenucciA, BastiC, and VerrottiA. The link between obesity and migraine in childhood: a systematic review. Ital J Pediatr, 43: 27, 2017.
104.
FerraraLA, PacioniD, Di FronzoV, RussoB, SperanzaE, CarlinoV, GargiuloF, and FerraraF. Low-lipid diet reduces frequency and severity of acute migraine attacks. Nutr Metab Cardiovasc Dis, 25: 370–375, 2015.
105.
FerrariMD, GoadsbyPJ, RoonKI, and LiptonRB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia, 22: 633–658, 2002.
106.
FerroniP, VazzanaN, RiondinoS, CuccurulloC, GuadagniF, and DavìG. Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal, 17: 1447–1485, 2012.
107.
FinocchiC and SivoriG. Food as trigger and aggravating factor of migraine. Neurol Sci, 33: S77–S80, 2012.
108.
FörstermannU and MünzelT. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation, 113: 1708–1714, 2006.
109.
FuentesE and PalomoI. Role of oxidative stress on platelet hyperreactivity during aging. Life Sci, 148: 17–23, 2016.
110.
FukaiT and Ushio-FukaiM. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal, 15: 1583–1606, 2011.
111.
FukaoT, LopaschukGD, and MitchellGA. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids, 70: 243–251, 2004.
FuscoBM, BarzoiG, and AgròF. Repeated intranasal capsaicin applications to treat chronic migraine. Br J Anaesth, 90: 812, 2003.
114.
GallaiV, FloridiA, MazzottaG, CodiniM, TognoloniM, VulcanoMR, SartoriM, RussoS, AlbertiA, MicheleF, and SarchielliP. L-arginine/nitric oxide pathway activation in platelets of migraine patients with and without aura. Acta Neurol Scand, 94: 151–160, 1996.
115.
García-MartínE, MartínezC, SerradorM, Alonso-NavarroH, NavacerradaF, AgúndezJA, and Jiménez-JiménezFJ. Paraoxonase 1 (PON1) polymorphisms and risk for migraine. J Neurol, 257: 1482–1485, 2010.
116.
GazzanigaPP, FerroniP, LentiL, LombardiD, MinaC, PulcinelliFM, RizzoP, and PontieriGM. Identification of blood leukotrienes in classical migraine. Headache, 27: 211–215, 1987.
117.
GBD. Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388: 1602, 2015.
118.
GentileG, NegroA, D'AlonzoL, AimatiL, SimmacoM, MartellettiP, and BorroM. Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population. Expert Rev Neurother, 15: 215–225, 2015.
119.
GerlachM, KehD, BezoldG, SpielmannS, KurerI, PeterRU, FalkeKJ, and GerlachH. Nitric oxide inhibits tissue factor synthesis, expression and activity in human monocytes by prior formation of peroxynitrite. Intensive Care Med, 24: 1199–1208, 1998.
120.
GerringZF, PowellJE, MontgomeryGW, and NyholtDR. Genome-wide analysis of blood gene expression in migraine implicates immune-inflammatory pathways. Cephalalgia, 2017. DOI: 10.1177/0333102416686769.
121.
GharibE, GardanehM, and ShojaeiS. Upregulation of glutathione peroxidase-1 expression and activity by glial cell line-derived neurotrophic factor promotes high-level protection of PC12 cells against 6-hydroxydopamine and hydrogen peroxide toxicities. Rejuvenation Res, 16: 185–199, 2013.
122.
GibbCM, DaviesPT, GloverV, SteinerTJ, Clifford RoseE, and SandlerM. Chocolate is a migraine-provoking agent. Cephalalgia, 11: 93–95, 1991.
123.
GkaliagkousiE, RitterJ, and FerroA. Platelet-derived nitric oxide signaling and regulation. Circ Res, 101: 654–662, 2007.
124.
GlaserCB, MorserJ, ClarkeJH, BlaskoE, McLeanK, KuhnI, ChangRJ, LinJH, VilanderL, AndrewsWH, and LightDR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest, 90: 2565–2573, 1992.
125.
GoadsbyPJ, EdvinssonL, and EkmanR. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol, 28: 183–187, 1990.
126.
GoadsbyPJ, HollandPR, Martins-OliveiraM, HoffmannJ, SchankinC, and AkermanS. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev, 97: 553–622, 2017.
127.
GoadsbyPJ. Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients. Brain, 139: 2571–2257, 2016.
128.
GolinoP, RagniM, CirilloP, AvvedimentoVE, FelicielloA, EspositoN, ScognamiglioA, TrimarcoB, IaccarinoG, CondorelliM, ChiarielloM, and AmbrosioG. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med, 2: 35–40, 1996.
129.
GomesA, CostaD, LimaJL, and FernandesE. Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?. Bioorg Med Chem, 14: 4568–4577, 2006.
130.
GonçalvesFM, LuizonMR, SpecialiJG, Martins-OliveiraA, DachF, and Tanus-SantosJE. Interaction among nitric oxide (NO)-related genes in migraine susceptibility. Mol Cell Biochem, 370: 183–189, 2012.
131.
GonçalvesFM, Martins-OliveiraA, SpecialiJG, LuizonMR, Izidoro-ToledoTC, SilvaPS, DachF, and Tanus-SantosJE. Endothelial nitric oxide synthase haplotypes associated with aura in patients with migraine. DNA Cell Biol, 30: 363–369, 2011.
132.
GoncalvesT, CarvalhoA, and OliveiraC. Antioxidant effect of calcium antagonists on microsomal membranes isolated from different brain areas. Eur J Pharmacol, 204: 315–322, 1991.
133.
González-QuintanillaV, TorielloM, PalacioE, González-GayMA, CastilloJ, MontesS, Martínez-NietoR, FernandezJ, RojoA, GutiérrezS, PonsE, and OterinoA. Systemic and cerebral endothelial dysfunction in chronic migraine. A case-control study with an active comparator. Cephalalgia, 36: 552–560, 2016.
134.
GörlachA. Redox regulation of the coagulation cascade. Antiox Redox Signal, 7: 1398–1404, 2005.
GovitrapongP, LimthavonC, and SrikiatkhachornA. 5-HT2 serotonin receptor on blood platelet of migraine patients. Headache, 32: 480–484, 1992.
137.
GrayE and BarrowcliffeTW. Inhibition of antithrombin III by lipid peroxides. Thromb Res, 37: 241–250, 1985.
138.
GrazziL, CorsiniE, CiusaniE, UsaiS, VascoC, and BussoneG. Evaluation of immune parameters in chronic migraine with medication overuse. Neurol Sci, 35: 171–173, 2014.
139.
GrinbergYY, van DrongelenW, and KraigRP. Insulin-like growth factor-1 lowers spreading depression susceptibility and reduces oxidative stress. J Neurochem, 122: 221–229, 2012.
140.
Guillemot-LegrisO and MuccioliG. Obesity-induced neuroinflammation: beyond the hypothalamus. Trends Neurosci, 40: 237–253, 2017.
141.
GuldikenS, GuldikenB, DemirM, KabayelL, OzkanH, TurgutN, HunkarR, and KatS. Soluble CD40 ligand and prolactin levels in migraine patients during interictal period. J Headache Pain, 12: 355–360, 2011.
142.
GuoS, ChristensenAF, LiuML, JanjooaBN, OlesenJ, and AshinaM. Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalalgia, 37: 114–124, 2016.
143.
GuoS, VollesenAL, OlesenJ, and AshinaM. Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain, 157: 2773–2781, 2016.
144.
GuptaR, KumarV, LuthraK, BanerjeeB, and BhatiaMS. Polymorphism in apolipoprotein and among migraineurs and tension-type headache subjects. J Headache Pain, 10: 115–120, 2009.
145.
HadjikhaniN, Sanchez del RioM, WuO, SchwartzD, BakkerD, FischlB, WongKK, CutrerFM, RosenBR, TootellRBH, SorensenAG, and MoskowitzMA. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A, 98: 4687–4692, 2001.
146.
HadjivassiliouM, SandersDS, GrunewaldRA, WoodroofeN, BoscoloS, and AeschlimannD. Gluten sensitivity: from gut to brain. Lancet Neurol, 9: 318–330, 2010.
147.
HaghdoostF, GharziM, FaezF, HosseinzadehE, TajaddiniM, Ra EiL, AsgariF, BanihashemiM, MasjediSS, ZandifarA, and Haghjooy-JavanmardS. Association between Ala379Val polymorphism of lipoprotein-associated phospholipase A2 and migraine without aura in Iranian population. Iran J Neurol, 15: 80–84, 2016.
148.
HandinRI, KarabinR, and BoxerGJ. Enhancement of platelet function by superoxide anion. J Clin Invest, 59: 959–965, 1977.
149.
HaningtonE, JonesRJ, AmessJA, and WachowiczB. Migraine: a platelet disorder. Lancet, 2: 720–723, 1981.
150.
HansenJM, HaugeAW, OlesenJ, and AshinaM. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia, 30: 1179–1186, 2010.
151.
HaorahJ, RamirezSH, FloreaniN, GorantlaS, MorseyB, and PersidskyY. Mechanism of alcohol-induced oxidative stress and neuronal injury. Free Radic Biol Med, 45: 1542–1550, 2008.
152.
HarrisonS and GeppettiP. Substance P. Int J Biochem Cell Biol, 33: 555–576, 2001.
153.
HaugeAW, KirchmannM, and OlesenJ. Trigger factors in migraine with aura. Cephalalgia, 30: 346–353, 2010.
154.
HayDL and WalkerCS. CGRP and its receptors. Headache, 57: 625–636, 2017. DOI: 10.1111/head.13064.
155.
Hering-HanitR, FriedmanZ, SchlesingerI, and EllisM. Evidence for activation of the coagulation system in migraine with aura. Cephalalgia, 21: 137–139, 2001.
156.
HewittDJ, AuroraSK, DodickDW, GoadsbyPJ, GeYJ, BachmanR, TaraborelliD, FanX, AssaidC, LinesC, and HoTW. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia, 31: 712–722, 2011.
157.
HoTW, HoAP, ChaitmanBR, JohnsonC, MathewNT, KostJ, FanX, AuroraSK, BrandesJL, FeiK, BeebeL, LinesC, and KrucoffMW. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache, 52: 224–235, 2012.
158.
HoTW, OlesenJ, DodickDW, KostJ, LinesC, and FerrariMD. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache, 51: 64–72, 2011.
159.
HoffmannJ and GoadsbyPJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol, 14: 50–59, 2012.
160.
HoffmannJ, SupronsinchaiW, AkermanS, AndreouAP, WinrowCJ, RengerJ, HargreavesR, and GoadsbyPJ. Evidence for orexinergic mechanisms in migraine. Neurobiol Dis, 74: 137–143, 2015.
161.
HoffmannJ, SupronsinchaiW, AkermanS, WinrowCJ, RengerJ, HargreavesR, and GoadsbyPJ. Nociceptive trigeminal neurotransmission is inhibited by the dual orexin receptor antagonist DORA-12. Cephalalgia, 33: S88–S89, 2013.
162.
HøivikHO, LaurijssensBE, HarnischLO, TwomeyCK, DixonRM, KirkhamAJ, WilliamsPM, WentzAL, and LunnonMW. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia, 30: 1458–1467, 2010.
163.
HolePS, DarleyRL, and TonksA. Do reactive oxygen species play a role in myeloid leukemias?. Blood, 117: 5816–5826, 2011.
164.
HollandP and GoadsbyPJ. The hypothalamic orexinergic system: pain and primary headaches. Headache, 47: 951–962, 2007.
165.
HollandPR, AkermanS, and GoadsbyPJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci, 24: 2825–2833, 2006.
166.
HollandPR, AkermanS, and GoadsbyPJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigemino-vascular nociception. J Pharmacol Exp Ther, 315: 1380–1385, 2005.
HolstegeG, BandlerR, and SaperCB. The emotional motor system. Prog Brain Res, 107: 3–6, 1996.
169.
HoyerD and JacobsonLH. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?. Neuropeptides, 47: 477–488, 2013.
170.
IJffDM, PostulartD, LambrechtsDA, MajoieMH, de KinderenRJ, HendriksenJG, EversSM, and AldenkampAP. Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: a randomized controlled trial. Epilepsy Behav, 60: 153–157, 2016.
171.
IniestaJA, CorralJ, González-ConejeroR, RiveraJ, and VicenteV. Prothrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease. Headache, 39: 486–489, 1999.
JeongEA, JeonBT, ShinHJ, KimN, LeeDH, KimHJ, KangSS, ChoGJ, ChoiWS, and RohGS. Ketogenic diet-induced peroxisome proliferator-activated receptor-γ activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures. Exp Neurol, 232: 195–202, 2011.
174.
JiaS, NiJ, ChenS, JiangY, DongW, and GaoY. Association of the pentanucleotide repeat polymorphism in NOS2 promoter region with susceptibility to migraine in a Chinese population. DNA Cell Biol, 30: 117–122, 2011.
175.
JiangH and BalazyM. Detection of 3-nitrotyrosine in human platelets exposed to peroxynitrite by a new gas chromatography/mass spectrometry assay. Nitric Oxide, 2: 350–359, 1998.
176.
JoshiG, PradhanS, and MittalB. Vascular gene polymorphisms (EDNRA −231 G>A and APOE HhaI) and risk for migraine. DNA Cell Biol, 30: 577–584, 2011.
177.
KandilEA, AbdelkaderNF, El-SayehBM, and SalehS. Imipramine and amitriptyline ameliorate the rotenone model of Parkinson's disease in rats. Neuroscience, 332: 26–37, 2016.
178.
KarsanN and GoadsbyPJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep, 15: 25, 2015.
179.
KashiwayaY, TakeshimaT, MoriN, NakashimaK, ClarkeK, and VeechRL. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci U S A, 97: 5440–5444, 2000.
180.
KatakamiN, KanetoH, MatsuokaTA, TakaharaM, ImamuraK, IshibashiF, KandaT, KawaiK, OsonoiT, KashiwagiA, KawamoriR, MatsuhisaM, ShimomuraI, and YamasakiY. Accumulation of gene polymorphisms related to oxidative stress is associated with myocardial infarction in Japanese type 2 diabetic patients. Atherosclerosis, 212: 534–538, 2010.
181.
KawaguchiK, MatsumotoT, and KumazawaY. Effects of antioxidant polyphenol on TNF-alpha-related disease. Curr Top Med Chem, 11: 1767–1779, 2011.
182.
KawaiT and AkiraS. TLR signaling. Cell Death Differ, 13: 816–825, 2006.
183.
KemperR, MeijlerW, KorfJ, and Ter HorstG. Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia, 21: 549–557, 2001.
184.
KhanS, SchoenenJ, and AshinaM. Sphenopalatine ganglion neuromodulation in migraine: what is the rationale?. Cephalalgia, 34: 382–391, 2014.
185.
KimDY, DavisLM, SullivanPG, MaaloufM, SimeoneTA, van BrederodeJ, and RhoJM. Ketone bodies are protective against oxidative stress in neocortical neurons. J Neurochem, 101: 1316–1326, 2007.
186.
KimMK, AhnSH, SonBH, and SungMK. Plasma antioxidant concentration, not superoxide dismutase polymorphism, is associated with breast cancer risk in Korean women. Nutr Res, 30: 705–713, 2010.
187.
KissigM, IshibashiJ, HarmsMJ, LimHW, StineRR, WonKJ, and SealeP. PRDM16 represses the type I interferon response in adipocytes to promote mitochondrial and thermogenic programing. EMBO J, 36: 1528–1542, 2017.
188.
KjaergaardM, EggenAE, MathiesenEB, and JordeR. Association between headache and serum 25-hydroxyvitamin D: the Tromso study: Tromso 6. Headache, 52: 1499–1505, 2012.
189.
KondratievaN, AzimovaJ, SkorobogatykhK, SergeevA, NaumovaE, KokaevaZ, AnuchinaA, RudkoO, TabeevaG, and KlimovE. Biomarkers of migraine: part 1—genetic markers. J Neurol Sci, 369: 63–76, 2016.
190.
KovačJ, Macedoni LukšičM, Trebušak PodkrajšekK, KlančarG, and BattelinoT. Rare single nucleotide polymorphisms in the regulatory regions of the superoxide dismutase genes in autism spectrum disorder. Autism Res, 7: 138–144, 2014.
191.
KozubskiW, WalkowiakB, CierniewskiCS, and PrusinskiA. Platelet fibrinogen receptors in migraine patients. Headache, 27: 431–434, 1987.
192.
KrönckeKD, FehselK, SuschekC, and Kolb-BachofenV. Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. Int Immunopharmacol, 1: 1407–1420, 2001.
193.
KrotzF, SohnHY, and PohlU. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol, 24: 1988–1996, 2004.
194.
KruitMC, LaunerLJ, FerrariMD, and van BuchemMA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain, 128: 2068–2077, 2005.
195.
KuboK, YoshitakeI, KumadaY, ShutoK, and NakamizoN. Radical scavenging action of flunarizine in rat brain in vitro. Arch Int Pharmacodyn Ther, 272: 283–295, 1984.
196.
KurthT, SchürksM, LogroscinoG, and BuringJE. Migraine frequency and risk of cardiovascular disease in women. Neurology, 73: 581–588, 2009.
197.
KurthT, WinterAC, EliassenAH, DushkesR, MukamalKJ, RimmEB, WillettWC, MansonJE, and RexrodeKM. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ, 353: i2610, 2016.
198.
La MancusaR, PulcinelliFM, FerroniP, LentiL, ManzariG, PauriF, RizzoP, GazzanigaPP, and PontieriGM. Blood leukotrienes in headache: correlation with platelet activity. Headache, 31: 409–414, 1991.
199.
LassenLH, AshinaM, ChristiansenI, UlrichV, and OlesenJ. Nitric oxide synthase inhibition in migraine. Lancet, 349: 401–402, 1997.
200.
LassenLH, HaderslevPA, JacobsenVB, IversenHK, SperlingB, and OlesenJ. CGRP may play a causative role in migraine. Cephalalgia, 22: 54–61, 2002.
201.
LassenLH, SperlingB, AndersenAR, and OlesenJ. The effect of i.v. L-NG methylarginine hydrochloride (L-NMMA: 546C88) on basal and acetazolamide (Diamox) induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man. Cephalalgia, 25: 344–352, 2005.
202.
LawrenceDA and LoskutoffDJ. Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry, 25: 6351–6355, 1986.
203.
LeH, Tfelt-HansenP, SkyttheA, KyvikKO, and OlesenJ. Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. J Headache Pain, 12: 157–172, 2011.
204.
LeãoAAP. Spreading depression of activity in cerebral cortex. J Neurophysiol, 7: 359–390, 1944.
205.
LeeWS, MoussaouiSM, and MoskowitzMA. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol, 112: 920–924, 1994.
206.
LevyRG, CooperPN, and GiriP. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev, 3: CD001903, 2012.
207.
LiL, DuJ, LianY, ZhangY, LiX, LiuY, ZouL, and WuT. Protective effects of coenzyme Q10 against hydrogen peroxide-induced oxidative stress in PC12 cell: the role of Nrf2 and antioxidant enzymes. Cell Mol Neurobiol, 36: 103–111, 2016.
208.
LinQ, PalecekJ, PaleckovaV, PengYB, WuJ, CuiM, and WillisWD. Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons. J Neurophysiol, 81: 1075–1085, 1999.
209.
LiptonRB, BigalME, DiamondM, FreitagF, ReedML, and StewartWF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68: 343–349, 2007.
210.
LiptonRB, FanningKM, SerranoD, ReedML, CadyR, and BuseDC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology, 84: 688–695, 2015.
211.
LiuH, MantyhPW, and BasbaumAI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature, 386: 721–724, 1997.
212.
LoRY, ShyuWC, LinSZ, WangHJ, ChenSS, and LiH. New molecular insights into cellular survival and stress responses: neuroprotective role of cellular prion protein (PrPC). Mol Neurobiol, 35: 236–244, 2007.
213.
LucchesiC, BaldacciF, CafalliM, ChicoL, Lo GerfoA, BonuccelliU, SicilianoG, and GoriS. Evidences of reduced antioxidant activity in patients with chronic migraine and medication-overuse headache. Headache, 55: 984–991, 2015.
214.
LucchiniRG, DormanDC, ElderA, and VeronesiB. Neurological impacts from inhalation of pollutants and the nose-brain connection. Neurotoxicology, 33: 838–841, 2012.
215.
LuoZD and CizkovaD. The role of nitric oxide in nociception. Curr Rev Pain, 4: 459–466, 2000.
216.
LynchJJJr, ReganCP, EdvinssonL, HargreavesRJ, and KaneSA. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol, 55: 518–521, 2010.
217.
MacGregorEA. Prevention and treatment of menstrual migraine. Drugs, 70: 1799–1818, 2010.
218.
MacknessMI, MacknessB, DurringtonPN, ConnellyPW, and HegeleRA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol, 7: 69–76, 1996.
219.
MagariñosAM and McEwenBS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: comparison of stressors. Neuroscience, 69: 83–88, 1995.
220.
MagroneT and JirilloE. Childhood obesity: immune responses and nutritional approaches. Front Immunol, 6: Article 76, 2015.
221.
MagroneT and JirilloE. Function and malfunction of the immune cell-adipocytes axis and its modulation by natural products and probiotics. Clin Immunol Endocr Metab Drug, 3: 39–46, 2016.
222.
MagroneT and JirilloE. Polyphenols from red wine are potent modulators of innate and adaptive immune responsiveness. Proc Nutr Soc, 69: 279–285, 2010.
223.
MagroneT and JirilloE. The interplay between the gut immune system and microbiota in health and disease: nutraceutical intervention for restoring intestinal homeostasis. Curr Pharm Dis, 19: 1329–1342, 2013.
224.
MagroneT, JirilloE, SpagnolettaA, MagroneM, RussoMA, FontanaS, LaforgiaF, DonvitoI, CampanellaA, SilvestrisF, and De PergolaG. Immune profile of obese people and in vitro effects of red grape polyphenols on peripheral blood mononuclear cells. Ox Med Cell Longev, 2017. DOI: 10.1155/2017/9210862.
225.
MaizelsM, ScottB, CohenW, and ChenW. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA, 276: 319–321, 1996.
226.
MaizelsM. Intranasal lidocaine to prevent headache following migraine aura. Headache, 39: 439–342, 1999.
227.
Manda-HandzlikA and DemkowU. Neutrophils: the role of oxidative and nitrosative stress in health and disease. Adv Exp Med Biol, 857: 51–60, 2015.
228.
ManzoniGC, CamardaC, and TorelliP. Chronification of migraine: what clinical strategies to combat it?. Neurol Sci, 34: S57–S60, 2013.
229.
MarcusAJ, SilkST, SafierLB, and UllmanHL. Superoxide production and reducing activity in human platelets. J Clin Invest, 59: 149–158, 1977.
230.
MarcusDA, ScharffL, TurkD, and GourleyLM. A double-blind provocative study of chocolate as a trigger of headache. Cephalalgia, 17: 855–862, 1997.
231.
MarcusR, GoadsbyPJ, DodickD, StockD, ManosG, and FischerTZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia, 34: 114–125, 2014.
MartinVT and VijB. Diet and headache: part I. Headache, 56: 1543–1552, 2016.
234.
MartinezM, WeiselJW, and IschiropoulosH. Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots. Free Radic Biol Med, 65: 411–418, 2013.
235.
Martínez-SánchezP, Martínez-MartínezM, FuentesB, CuestaMV, Cuéllar-GamboaL, Idrovo-FreireL, Fernández-DominguezJ, and Díez-TejedorE. Migraine and hypercoagulable states in ischemic stroke. Cephalalgia, 31: 1609–1617, 2011.
236.
MarzulliG, MagroneT, KawaguchiK, KumazawaY, and JirilloE. Fermented grape marc (FGM): immunomodulating properties and its potential exploitation in the treatment of neurodegenerative diseases. Curr Pharm Des, 18: 43–50, 2012.
237.
MarzulliG, MagroneT, VonghiaL, KanekoM, TakimotoH, KumazawaY, and JirilloE. Immunomodulating and anti-allergic effects of Negroamaro and Koshu Vitis vinifera Fermented grape marc (FGM). Curr Pharm Des, 20: 864–868, 2014.
238.
MaschbergerP, BauerM, Baumann-SiemonsJ, ZanglKJ, NegrescuEV, ReiningerAJ, and SiessW. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. J Biol Chem, 275: 19159–19166, 2000.
239.
MatesanzF, FedetzM, BarrionuevoC, KarakyM, Catalá-RabasaA, PotencianoV, Bello-MoralesR, López-GuerreroJA, and AlcinaA. A splice variant in the ACSL5 gene relates migraine with fatty acid activation in mitochondria. Eur J Hum Genet, 24: 1572–1577, 2016.
240.
MayA and GoadsbyPJ. Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs, 10: 673–678, 2001.
241.
MayerEA. The neurobiology of stress and gastrointestinal disease. Gut, 47: 861–869, 2000.
242.
McIntyreKJ, HoaglandHC, SilversteinMN, and PetittRM. Essential thrombocythemia in young adults. Mayo Clin Proc, 66: 149–154, 1991.
243.
MedveRA and LateganTW. A phase 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled study of NXN-188 dihydrochloride in acute migraine without aura. J Headache Pain, 11: S38, 2010.
244.
MenonR, LeaA, RoyB, HannaM, WeeS, HauptLM, OliverC, and GriffithsLR. Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation. Pharmacogenet Genomics, 22: 741–749, 2012.
245.
MerikangasKR. Contributions of epidemiology to our understanding of migraine. Headache, 53: 230–246, 2013.
246.
MerrettJ, PeatfieldRC, RoseFC, and MerrettTG. Food related antibodies in headache patients. J Neurol Neurosurg Psychiatry, 46: 738–742, 1983.
247.
MesslingerK, LennerzJK, EberhardtM, and FischerMJ. CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache, 52: 1411–1427, 2012.
248.
MiaoJ, WangF, ZhengW, and ZhuangX. Association of the Apolipoprotein and polymorphism with migraine: a meta-analysis. BMC Neurol, 15: 138, 2015.
249.
MiaoL and St ClairDK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med, 47: 344–356, 2009.
250.
MiyataM and SmithJD. Apolipoprotein and allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet, 14: 55–61, 1996.
251.
MondoroTH, ShaferBC, and VostalJG. Peroxynitrite-induced tyrosine nitration and phosphorylation in human platelets. Free Radic Biol Med, 22: 1055–1063, 1997.
252.
MoroMA, Darley-UsmarVM, GoodwinDA, ReadNG, Zamora-PinoR, FeelischM, RadomskiMW, and MoncadaS. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci U S A, 91: 6702–6706, 1994.
253.
MoschianoF, D'AmicoD, CiusaniE, ErbaN, RigamontiA, SchieroniF, and BussoneG. Coagulation abnormalities in migraine and ischaemic cerebrovascular disease: a link between migraine and ischaemic stroke?. Neurol Sci, 25: S126–S128, 2004.
254.
MoskowitzMA, ReinhardJFJr, RomeroJ, and MelamedEN. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine?. Lancet, 2: 883–885, 1979.
255.
MoskowitzMA. The neurobiology of vascular head pain. Ann Neurol, 16: 157–168, 1984.
256.
MussoG, GambinoR, and CasasderM. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?. Diabetes Care, 33: 2277–2284, 2010.
257.
NennaR, PetrarcaL, VerdecchiaP, FlorioM, MastrogiorgioG, BavastrelliM, BonamicoM, and CucchiaraS. Celiac disease in a large cohort of children and adolescents with recurrent headache: a retrospective study. Dig Liver Dis, 48: 495–498, 2016.
258.
NeriM, FrustaciA, MilicM, ValdiglesiasV, FiniM, BonassiS, and BarbantiP. A meta-analysis of biomarkers related to oxidative stress and nitric oxide pathway in migraine. Cephalalgia, 35: 931–937, 2015.
259.
NicolasO, GavínR, and del RíoJA. New insights into cellular prion protein (PrPc) functions: the “ying and yang” of a relevant protein. Brain Res Rev, 61: 170–184, 2009.
260.
NilsenJ and Diaz BrintonR. Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci U S A, 100: 2842–2847, 2003.
261.
NowakP and WachowiczB. Peroxynitrite-mediated modification of fibrinogen affects platelet aggregation and adhesion. Platelets, 13: 293–299, 2002.
262.
OlesenJ, DienerH, HusstedtI, GoadsbyPJ, HallD, MeierU, PollentierS, and LeskoLM; BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med, 350: 1104–1110, 2004.
263.
OlesenJ, LarsenB, and LauritzenM. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol, 9: 344–352, 1981.
264.
OlesenJ, ThomsenLL, and IversenH. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci, 15: 149–153, 1994.
265.
OlesenJ, ThomsenLL, LassenLH, and OlesenIJ. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia, 15: 94–100, 1995.
266.
OlesenJ. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther, 120: 157–171, 2008.
267.
OwenOE, MorganAP, KempHG, SullivanJM, HerreraMG, and CahillGFJr. Brain metabolism during fasting. J Clin Invest, 46: 1589–1595, 1967.
268.
PalmerJE, GuillardFL, LaurijssensBE, WentzAL, DixonRM, and WilliamsPM. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia, 29: 124, 2009.
269.
PalmirottaR, BarbantiP, De MarchisML, EgeoG, AuriliaC, FofiL, IalongoC, ValenteMG, FerroniP, Della-MorteD, and GuadagniF. Is SOD2 Ala16Val polymorphism associated with migraine with aura phenotype?. Antioxid Redox Signal, 22: 275–279, 2015.
270.
PalmirottaR, BarbantiP, LudoviciG, EgeoG, AuriliaC, FofiL, De MarchisML, SpilaA, FerroniP, Della-MorteD, and GuadagniF. Establishment of a biorepository for migraine research: the experience of Interinstitutional Multidisciplinary BioBank (BioBIM). Neurol Sci, 34: 1659–1663, 2013.
271.
PalmirottaR, LudoviciG, EgeoG, IalongoC, AuriliaC, FofiL, De MarchisML, Della-MorteD, BarbantiP, and GuadagniF. Prion protein gene M129V polymorphism and variability in age at migraine onset. Headache, 53: 540–545, 2013.
272.
PanduruNM, CimponeriuD, CruceM, IonDA, MoţaE, MoţaM, SerafinceanuC, ChivuLI, PanduruM, ChivuRD, and CovicAC. Association of +35A/C (intron3/exon3) polymorphism in SOD1-gene with diabetic nephropathy in type 1 diabetes. Rom J Morphol Embryol, 51: 37–41, 2010.
273.
PanieriE and SantoroMM. ROS signaling and redox biology in endothelial cells. Cell Mol Life Sci, 72: 3281–3303, 2015.
274.
PaoliA, RubiniA, VolekJS, and GrimaldiKA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr, 67: 789–796, 2013.
275.
ParkSJ, LeeJH, KimHY, ChoiYH, ParkJS, SuhYH, ParkSM, JoeEH, and JouI. Astrocytes, but not microglia, rapidly sense H(2)O(2)via STAT6 phosphorylation, resulting in cyclooxygenase-2 expression and prostaglandin release. J Immunol, 188: 5132–5141, 2012.
276.
PastoriD, PignatelliP, CarnevaleR, and VioliF. Nox-2 up-regulation and platelet activation: novel insights. Prostaglandins Other Lipid Mediat, 120: 50–55, 2015.
277.
PawlowskaZ, KozubskiW, WalkowiakB, and CierniewskiCS. Increased platelet glycoprotein IIb reflects an abnormality of the platelet membrane in migraine. Headache, 28: 60, 1988.
278.
PeatfieldRC. Can transient ischaemic attacks and classical migraine always be distinguished?. Headache, 27: 240–243, 1987.
279.
PerezRS, ZollingerPE, DijkstraPU, Thomassen–HilgersomIL, ZuurmondWW, RosenbrandKC, GeertzenTH, and CRPSI Task. Evidence based guidelines for complex regional pain syndrome type 1. BMC Neurol, 10: 20, 2010.
280.
PeriniF, D'AndreaG, GalloniE, PignatelliF, BilloG, AlbaS, BussoneG, and TosoV. Plasma cytokine levels in migraineurs and controls. Headache, 45: 926–931, 2005.
281.
PeterlinBL, BigalME, TepperSI, UrakazeM, SheftellFD, and RapoportAM. Migraine and adiponectin: is there a connection?. Cephalalgia, 27: 435–446, 2007.
282.
PeterlinBL, RossoAI, RapoportAM, and ScherAI. Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache, 50: 52–62, 2010.
283.
PeterlinBL, RossoAL, Williams MA RosenbergJR, HaythomthwaiteJA, MerikangasKR, GottesmanRF, BondsDF, HeJP, and ZondermanAB. Episodic migraine and obesity and the influence of age, race and sex. Neurology, 81: 1314–1321, 2013.
284.
PeterlinBL, SaccoS, BerneckerC, and ScherAI. Adipokines and migraine: a systematic review. Headache, 56: 622–644, 2016.
285.
PietraforteD, VonaR, MarchesiA, de JacobisIT, VillaniA, Del PrincipeD, and StrafaceE. Redox control of platelet functions in physiology and pathophysiology. Antioxid Redox Signal, 21: 177–193, 2014.
286.
PietrobonD and MoskowitzMA. Pathophysiology of migraine. Annu Rev Physiol, 75: 365–391, 2013.
287.
PlaisanceEP, GrandjeanPW, JuddRL, JonesKW, and TaylorJK. The influence of sex, body composition, and non esterified fatty acids on serum adipokine concentrations. Metabolism, 58: 1557–1563, 2009.
288.
PodrezEA, ByzovaTV, FebbraioM, SalomonRG, MaY, ValiyaveettilM, PoliakovE, SunM, FintonPJ, CurtisBR, ChenJ, ZhangR, SilversteinRL, and HazenSL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med, 13: 1086–1095, 2007.
289.
PowerJH and BlumbergsPC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol, 117: 63–73, 2009.
290.
PrastH and PhilippuA. Nitric oxide as modulators of neuronal function. Prog Neurobiol, 64: 51–68, 2001.
291.
PuleddaF, MessinaR, and GoadsbyPJ. An update on migraine: current understanding and future directions. J Neurol, 2017. DOI: 10.1007/s00415-017-8434-y.
RaddantAC and RussoAF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med, 13: e36, 2011.
294.
RahmannA, WieneckeT, HansenJM, FahrenkrugJ, OlesenJ, and AshinaM. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia, 28: 226–236, 2008.
295.
RaineroI, GrimaldiLM, SalaniG, ValfrèW, SaviL, RivoiroC, GentileS, and PinessiL. Apolipoprotein and gene polymorphisms in patients with migraine. Neurosci Lett, 317: 111–113, 2002.
296.
RaineroI, RubinoE, GalloneS, FenoglioP, PicciLR, GiobbeL, OstacoliL, and PinessiL. Evidence for an association between migraine and the hypocretin receptor 1 gene. J Headache Pain, 12: 193–139, 2011.
297.
RamsdenCE, FaurotKR, ZamoraD, SuchimdranCM, MacintoshBA, GaylordS, RingelA, HibbeinJR, FeldsteinAE, MoriTA, BardenA, LynchC, CobleR, MasE, PallsonO, BarrowDA, and MannJD. Targeted alterations of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain, 154: 2441–2451, 2013.
298.
RazaviaBM and HosseinzadehH. A review of the role of orexin system in pain modulation. Biomed Pharmacother, 90: 187–193, 2017.
299.
RecoberA and GoadsbyP. Calcitonin gene-related peptide: a molecular link between obesity and migraine?. Drug News Perspect, 23: 112–117, 2010.
300.
RegoliD, BoudonA, and FauchéreJL. Receptors and antagonists for substance P and related peptides. Pharmacol Rev, 46: 551–599, 1994.
301.
ReyC, VericelE, NemozG, ChenW, ChapuyP, and LagardeM. Purification and characterization of glutathione peroxidase from human blood platelets. Age-related changes in the enzyme. Biochim Biophys Acta, 1226: 219–224, 1994.
302.
RiescoN, Cernuda-MorollónE, and PascualJ. Neuropeptides as a marker for chronic headache. Curr Pain Headache Rep, 21: 18, 2017.
303.
RussellFA, KingR, SmillieSJ, KodjiX, and BrainSD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev, 94: 1099–1142, 2014.
304.
SabetkarM, LowSY, NaseemKM, and BruckdorferKR. The nitration of proteins in platelets: significance in platelet function. Free Radic Biol Med, 33: 728–736, 2002.
305.
SachsD, CunhaF, PooleS, and FerreiraS. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain, 96: 89–97, 2002.
306.
SalveminiD, De NucciG, and VaneJR. Superoxide dismutase cooperates with prostacyclin to inhibit platelet aggregation: a comparative study in washed platelets and platelet rich plasma. Thromb Haemost, 65: 421–424, 1991.
307.
SalveminiD, De NucciG, SneddonM, and VaneJR. Superoxide anions enhance platelet adhesion and aggregation. Br J Pharmacol, 97: 1145–1150, 1989.
308.
SarchielliP, AlbertiA, CoppolaF, BaldiA, GallaiB, FloridiA, FloridiA, CapocchiG, and GallaiV. Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks. Cephalalgia, 24: 623–630, 2004.
309.
SarchielliP, PiniLA, ZanchinG, AlbertiA, MaggioniF, RossiC, FloridiA, and CalabresiP. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia, 26: 257–265, 2006.
310.
SarchielliP, RaineroI, CoppolaF, RossiC, ManciniM, PinessiL, and CalabresiP. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia, 28: 714–722, 2008.
311.
SaruwatariJ, DeguchiM, YoshimoriY, NoaiM, YoshidaS, OgusuN, OnikiK, YoshidaS, Yasui-FurukoriN, KanekoS, IshitsuT, and NakagawaK. Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases. Epilepsy Res, 99: 183–186, 2012.
312.
SatoH, ShibataM, ShimizuT, ShibataS, ToriumiH, EbineT, KuroiT, IwashitaT, FunakuboM, KayamaY, AkazawaC, WajimaK, NakagawaT, OkanoH, and SuzukiN. Differential cellular localization of antioxidant enzymes in the trigeminal ganglion. Neuroscience, 248: 345–358, 2013.
313.
SattarN, WannametheeG, SarwarN, ChemovaJ, LawlorDA, KellyA, WallaceAM, DaneshJ, and WhincupPH. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol, 53: 167–175, 2009.
314.
SaygiS, Erol İ, AlehanF, YalçınYY, KubatG, and AtaçFB. Superoxide dismutase and catalase genotypes in pediatric migraine patients. J Child Neurol, 30: 1586–1590, 2015.
315.
SchäfersM, SommerC, GeisC, HagenackerT, VandenabeeleP, and SorkinLS. Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience, 157: 414–423, 2008.
316.
ScherAI, LiptonRB, StewartWF, and BigalM. Patterns of medication use by chronic and episode headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia, 30: 321–328, 2010.
317.
ScherAI, StewartWF, RicciJA, and LiptonRB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain, 106: 81–89, 2003.
318.
SchiavoneS, SorceS, Dubois-DauphinM, JaquetV, ColaiannaM, ZottiM, CuomoV, TrabaceL, and KrauseKH. Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry, 66: 384–392, 2009.
319.
SchmitzN, Admiraal-BehloulF, ArkinkEB, KruitMC, SchoonmanGG, FerrariMD, and van BuchemMA. Attack frequency and disease duration as indicators for brain damage in migraine. Headache, 48: 1044–1055, 2008.
320.
SchoenenJ, JacquyJ, and LenaertsM. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology, 50: 466–470, 1998.
321.
SchrammSH, MoebusS, Ozyurt KugumcuM, GeiselMH, ObermannM, YoonMS, JockelKH, and KatsaravaZ. Use of aspirin combinations with caffeine and increasing headache frequency: a prospective population-based study. Pain, 156: 1747–1754, 2015.
322.
SchürksM, RistPM, BigalME, BuringJE, LiptonRB, and KurthT. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ, 339: b3914, 2009.
323.
SchytzHW, OlesenJ, and AshinaM. The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics, 7: 191–196, 2010.
324.
SensenigJ, JohnsonM, and StaveroskyT. Treatment of migraine with targeted nutrition focused on improved assimilation and elimination. Altern Med Rev, 6: 488–494, 2001.
325.
ShatilloA, KorolevaK, GiniatullinaR, NaumenkoN, SlastnikovaAA, AlievRR, BartG, AtalayM, GuC, KhazipovR, DavletovB, GrohnO, and GiniatullinR. Cortical spreading depression induces oxidative stress in the trigeminal nociceptive system. Neuroscience, 253: 341–349, 2013.
326.
ShermanL, DafniN, Lieman-HurwitzJ, and GronerY. Nucleotide sequence and expression of human chromosome 21-encoded superoxide dismutase mRNA. Proc Natl Acad Sci U S A, 80: 5465–5469, 1983.
327.
ShimomuraT, KowaH, NakanoT, KitanoA, MarukawaH, UrakamiK, and TakahashiK. Platelet superoxide dismutase in migraine and tension-type headache. Cephalalgia, 14: 215–218, 1994.
328.
ShimomuraT, MurakamiF, KotaniK, IkawaS, and KonoS. Platelet nitric oxide metabolites in migraine. Cephalalgia, 19: 218–222, 1999.
329.
SicuteriF, DelbeneE, PoggioniM, and BonazziA. Unmasking latent dysnociception in healthy-subjects. Headache, 27: 180–185, 1987.
330.
SiegelJM. Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psycol, 55: 125–148, 2004.
SindelarJJ and MilkwoskiAl. Human safety controversies surrounding nitrate and nitrite in the diet. Nitric Oxide, 25: 259–266, 2012.
333.
SitiHN, KamisahY, and KamsiahJ. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol, 71: 40–56, 2015.
334.
SokołowskaP, UrbańskaA, BiegańskaK, WagnerW, CiszewskiW, NamiecińskaM, and ZawilskaJB. Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling. J Mol Neurosci, 52: 48–55, 2014.
335.
SomjenGG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol Rev, 81: 1065–1096, 2001.
336.
SonegoG, AbonnencM, TissotJD, PrudentM, and LionN. Redox proteomics and platelet activation: understanding the redox proteome to improve platelet quality for transfusion. Int J Mol Sci, 18: E387, 2017.
337.
SorgatoMC, SartorelliL, LoschenG, and AzziA. Oxygen radicals and hydrogen peroxide in rat brain mitochondria. FEBS Lett, 45: 92–95, 1974.
338.
StamlerJS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell, 23: 931–936, 1994.
339.
StangP, SternfeldB, and SidneyS. Migraine headache in a prepaid health plan: ascertainment, demographics, physiological, and behavioral factors. Headache, 36: 69–76, 1966.
340.
StewartWF, BigalME, KolodnerK, DowsonA, LibermanJN, and LiptonRB. Familial risk of migraine: variation by proband age at onset and headache severity. Neurology, 66: 344–348, 2006.
341.
StewartWF, LinetMS, CelentanoDD, Van NattaM, and ZieglerD. Age and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol, 34: 1111–1120, 1991.
342.
StewartWF, RoyJ, and LiptonR. Migraine prevalence, socioeconomic status, and social causation. Neurology, 81: 948–955, 2013.
343.
StiefTW, AabA, and HeimburgerH. Oxidative inactivation of purified human alpha-2-antiplasmin, antithrombin III, and C1-inhibitor. Thromb Res, 49: 581–589, 1988.
344.
StorerRJ, AkermanS, and GoadsbyPJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol, 142: 1171–1181, 2004.
345.
StuartMJ and HolmsenH. Hydrogen peroxide, an inhibitor of platelet function: effect on adenine nucleotide metabolism, and the release reaction. Am J Hematol, 2: 53–63, 1977.
346.
StuartS, DongesB, MurrellM, HauptLM, LeaRA, and GriffithsLR. Investigation of APOE isoforms and the association between APOE E3 and E4 with migraine in the Australian Caucasian population. Neuroreport, 24: 499–503, 2013.
347.
SunH, DodickDW, SilbersteinS, GoadsbyPJ, ReuterU, AshinaM, SaperJ, CadyR, ChonY, DietrichJ, and LenzR. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol, 15: 382–390, 2016.
348.
TaffiR, VigniniA, LanciottiC, LuconiR, NanettiL, MazzantiL, ProvincialiL, SilvestriniM, and BartoliniM. Platelet membrane fluidity and peroxynitrite levels in migraine patients during headache-free periods. Cephalalgia, 25: 353–358, 2005.
349.
TajtiJ, SzokD, MajláthZ, TukaB, CsátiA, and VécseiL. Migraine and neuropeptides. Neuropeptides, 52: 19–30, 2015.
350.
TakajoY, IkedaH, HaramakiN, MuroharaT, and ImaizumiT. Augmented oxidative stress of platelets in chronic smokers. Mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol, 38: 1320–1327, 2001.
351.
TakanoT, TianGF, PengW, LouN, LovattD, HansenAJ, KasischkeKA, and NedergaardM. Cortical spreading depression causes and coincides with tissue hypoxia. Nat Neurosci, 10: 754–762, 2007.
352.
TaylorFR. Tobacco, nicotine, and headache. Headache, 55: 1028–1044, 2015.
353.
TepperS, AshinaM, ReuterU, BrandesJL, DoležilD, SilbersteinS, WinnerP, LeonardiD, MikolD, and LenzR. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol, 16: 425–434, 2017.
354.
Tfelt-HansePC and KoehlerPJ. One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. Headache, 51: 752–778, 2011.
355.
ThomasSR, WittingPK, and DrummondGR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal, 10: 1713–1765, 2008.
356.
ThomsenLL and OlesenJ. Nitric oxide theory of migraine. Clin Neurosci, 5: 28–33, 1998.
357.
ThomsenLL, KruuseC, IversenHK, and OlesenJ. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol, 1: 73–80, 1994.
358.
ThundyilJ, PavlovskiD, SobeyCG, and ArumugamTV. Adiponectin receptor signaling in the brain. Br J Pharmacol, 165: 313–327, 2012.
359.
TietjenGE, Al-QasmiMM, AthanasK, UtleyC, and HerialNA. Altered hemostasis in migraineurs studied with a dynamic flow system. Thromb Res, 119: 217–222, 2007.
360.
TietjenGE and CollinsSA. Hypercoagulability and Migraine. Headache, 2017. DOI: 10.1111/head.13044.
361.
TietjenGE, HerialNA, WhiteL, UtleyC, KosmynaJM, and KhuderSA. Migraine and biomarkers of endothelial activation in young women. Stroke, 40: 2977–2982, 2009.
362.
TilgH and MoschenAR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol, 6: 772–783, 2006.
363.
TodaN, AyajikiK, and OkamuraT. Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol Rev, 61: 62–97, 2009.
364.
TozziA, de IureA, Di FilippoM, CostaC, CaproniS, PisaniA, BonsiP, PicconiB, CupiniLM, MaterazziS, GeppettiP, SarchielliP, and CalabresiP. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A, 109: 18985–18990, 2012.
365.
VadsethC, SouzaJM, ThomsonL, SeagravesA, NagaswamiC, ScheinerT, TorbetJ, VilaireG, BennettJS, MurcianoJC, MuzykantovV, PennMS, HazenSL, WeiselJW, and IschiropoulosH. Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem. 279: 8820–8826, 2004.
366.
Van der SchuerenBJ, LunnonMW, LaurijssensBE, GuillardF, PalmerJ, Van HeckenA, DepréM, VanmolkotFH, and de HoonJN. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?. J Clin Pharmacol, 49: 281–290, 2009.
367.
van DongenRM, ZielmanR, NogaM, DekkersOM, HankemeierT, van den MaagdenbergAMJM, TerwindtGM, and FerrariMD. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia, 37: 49–63, 2017.
368.
VanitallieTB, NonasC, Di RoccoA, BoyarK, HyamsK, and HeymsfieldSB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology, 64: 728–730, 2005.
369.
VarkeyE, CiderA, CarlssonJ, and LindeM. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia, 31: 1428–1438, 2011.
370.
VarkeyE, HagenK, ZwartJA, and LindeM. Physical activity and headache: results from the Nord-Trøndelag Health Study (HUNT). Cephalalgia, 28: 1292–1297, 2008.
371.
VauseCV and DurhamPL. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem, 110: 811–821, 2009.
372.
VeechRL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids, 7: 309–319, 2004.
373.
VergatiM, KrasniqiE, Del MonteG, RiondinoS, ValloneD, GuadagniF, FerroniP, and RoselliM. Ketogenic diet and other dietary intervention strategies in the treatment of cancer. Curr Med Chem, 24: 1170–1185, 2017. DOI: 10.2174/0929867324666170116122915.
374.
VermeerLM, GregoryE, WinterMK, McCarsonKE, and BermanNE. Behavioral effects and mechanisms of migraine pathogenesis following estradiol exposure in a multibehavioral model of migraine in rat. Exp Neurol, 263: 8–16, 2015.
375.
VetvikKG and MacGregorEA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol, 16: 76–87, 2017.
376.
ViggianoA, ViggianoE, ValentinoI, MondaM, ViggianoA, and De LucaB. Cortical spreading depression affects reactive oxygen species production. Brain Res, 1368: 11–18, 2011.
377.
VoM, AinalemA, QiuC, PeterlinBL, AuroraSK, and WilliamsMA. Body mass index and adult weight gain among reproductive age women with migraine. Headache, 51: 559–569, 2011.
378.
VossT, LiptonRB, DodickDW, DupreN, GeJY, BachmanR, AssaidC, AuroraSK, and MichelsonD. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia, 36: 887–898, 2016.
379.
WalkowiakB, KozubskiW, PawlowskaZ, PrusinskiA, and CierniewskiCS. Expression of fibrinogen receptors in platelets of migraine patients—correlation with platelet GPIIb content and plasma cholesterol. Thromb Haemost, 61: 419–422, 1989.
380.
WangSS, DavisS, CerhanJR, HartgeP, SeversonRK, CozenW, LanQ, WelchR, ChanockSJ, and RothmanN. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis, 27: 1828–1834, 2006.
381.
WantkeF, GotzM, and JarischR. The red wine provocation test: intolerance to histamine as a model for food intolerance. Allergy Proc, 15: 27–32, 1994.
382.
WelchKM, NageshV, AuroraSK, and GelmanN. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache, 41: 629–637, 2001.
383.
WöberC, BrannathW, SchmidtK, KapitanM, RudelE, WesselyP, and Wöber-BingölC; PAMINA Study Group. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia, 27: 304–314, 2007.
384.
WöberC, HolzhammerJ, ZeitlhoferJ, WesselyP, and Wöber-BingölC. Trigger factors of migraine and tension-type headache: experience and knowledge of the patients. J Headache Pain, 7: 188–195, 2006.
385.
WuJ, FangL, LinQ, and WillisWD. Nitric oxide synthase in spinal cord central sensitization following intradermal injection of capsaicin. Pain, 94: 47–58, 2001.
386.
YıldırımS, AkarS, KuyucuM, YıldırımA, DaneS, and AygülR. Paraoxonase 1 gene polymorphisms, paraoxonase/arylesterase activities and oxidized low-density lipoprotein levels in patients with migraine. Cell Biochem Funct, 29: 549–554, 2011.
387.
YilmazG, SürerH, InanLE, CoskunO, and YücelD. Increased nitrosative and oxidative stress in platelets of migraine patients. Tohoku J Exp Med, 211: 23–30, 2007.
388.
YipJ and ChahlLA. Localization of NK1 and NK3 receptors in guinea-pig brain. Regul Pept, 98: 55–62, 2001.
ZaeemZ, ZhouL, and DilliE. Headaches: a review of the role of dietary factors. Curr Neurol Neurosci Rep, 16: 101, 2016.
391.
ZelissenP, KoppeschaarH, LipsC, and HackengW. Calcitonin gene-related peptide in human obesity. Peptides, 12: 861–863, 1991.
392.
ZellerJA, FrahmK, BaronR, StingeleR, and DeuschlG. Platelet-leukocyte interaction and platelet activation in migraine: a link to ischemic stroke?. J Neurol Neurosurg Psychiatry, 75: 984–987, 2004.
393.
ZellerJA, LindnerV, FrahmK, BaronR, and DeuschlG. Platelet activation and platelet-leucocyte interaction in patients with migraine. Subtype differences and influence of triptans. Cephalalgia, 25: 536–541, 2005.
394.
ZhangX, LevyD, KainzV, NosedaR, JakubowskiM, and BursteinR. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol, 69: 855–865, 2011.
395.
ZhangX, LevyD, NosedaR, KainzV, JakubowskiM, and BursteinR. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci, 30: 8807–8814, 2010.
396.
ZhaoZ, LangeDJ, VoustianioukA, MacGroganD, HoL, SuhJ, HumalaN, ThiyagarajanM, WangJ, and PasinettiGM. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci, 7: 29, 2006.
397.
ZhouL and ZhuDY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide, 20: 223–230, 2009.
